Laboratory	CPT Code	Long Descriptor	Short Descriptor
clonoSEQAssay, Adaptive Biotechnologies	0364U	Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate	ONC HL NEO GEN SEQ ALYS ALG
Oncuria Detect, DiaCarta Clinical Lab, DiaCarta, Inc	0365U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as probability of bladder cancer	ONC BLDR 10 PRB BLDR CA
Oncuria Monitor, DiaCarta Clinical Lab, DiaCarta, Inc	0366U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, algorithm reported as probability of recurrent bladder cancer	ONC BLDR 10 PRB RECR BLDR CA
Oncuria Predict, DiaCarta Clinical Lab, DiaCarta, Inc	0367U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1, and VEGFA) by immunoassays, urine, diagnostic algorithm reported as risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection	ONC BLDR 10 FLWG TRURL RESCJ
GI assay (Gastrointestinal Pathogen with ABR), Lab Genomics LLC, Thermo Fisher Scientific	0369U	Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique	IADNA GI PTHGN 31 ORG&21 ARG
Lesion Infection (Wound), Lab Genomics LLC, Thermo Fisher Scientific	0370U	Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab	IADNA SURG WND PTHGN 34&21
Qlear UTI, Lifescan Labs of Illinois, Thermo Fisher Scientific	0371U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine	IADNA GU PTHGN SEMIQ DNA16&1
Qlear UTI - Reflex ABR, Lifescan, Labs of Illinois, Thermo Fisher Scientific	0372U	Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score	NFCT DS GU PTHGN ARG DETCJ
Respiratory Pathogen with ABR (RPX), Lab Genomics LLC, Thermo Fisher Scientific	0373U	Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen	IADNA RSP TR NFCT 17 8 13&16
Urogenital Pathogen with Rx Panel (UPX), Lab Genomics LLC, Thermo Fisher Scientific	0374U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine	IADNA GU PTHGN 21 ORG&21ARG
OvaWatchSM, Aspira Women's HealthSM, Aspira Labs, Inc	0375U	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [i.e., transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score	ONC OVRN BCHM ASY 7 PRTN ALG
ArteraAI Prostate Test, Artera Inc	0376U	Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation therapy response, if appropriate	ONC PRST8 CA IMG ALYS 128
Liposcale, CIMA Sciences, LLC	0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)	CV DS QUAN ADVSRM/PLSM LPRTN

UCGSL RFC1 Repeat Expansion Test, University of Chicago Genetic Services Laboratories	0378U	RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab	RFC1 REPEAT XPNSJ VRNT ALYS
Solid Tumor Expanded Panel, Quest Diagnostics	0379U	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden	TGSAP SL OR NEO DNA523&RNA55
PersonalisedRX, Lab Genomics LLC, Agena Bioscience, Inc	0380U	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and CYP2D6 deletion or duplication analysis with reported genotype and phenotype	RX METB ADVRS TRGT SQ ALY 20
Branched-Chain Amino Acids, SelfCollect, Blood Spot, Mayo Clinic, Laboratory Developed Test	0381U	Maple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of alloisoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)	MAPLE SYRUP UR DS MNTR QUAN
Phenylalanine and Tyrosine, SelfCollect, Blood Spot, Mayo Clinic, Laboratory Developed Test	0382U	Hyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)	HYPRPHENYLALNI NMIA MNTR QUAN
Tyrosinemia FollowUp Panel, SelfCollect, Blood Spot, Mayo Clinic, Laboratory Developed Test	0383U	Tyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitisinone, liquid chromatography with tandem mass spectrometry (LC-MS/MS)	TYROSINEMIA TYP I MNTR QUAN
NaviDKDTM Predictive Diagnostic Screening for Kidney Health, Journey Biosciences, Inc	0384U	Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease	NEPH CKD RSK HI STG KDN DS
PromarkerD, Sonic Reference Laboratory, Proteomics International Pty Ltd	0385U	Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as risk score for developing diabetic kidney disease	NEPH CKD ALG RSK DBTC KDN DS
Envisage, Capsulomics, Inc	0386U	Gastroenterology (Barrett's esophagus), P16, RUNX3, HPP1, and FBN1 methylation analysis, prognostic and predictive algorithm reported as a risk score for progression to high-grade dysplasia or esophageal cancer	GI BARRETT ESOPH MTHYLTN ALY